The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this Phase III, randomized, double-blind, placebo-controlled study in
patients with immunologic deficiency is to determine the effect of Isoprinosine in producing
an immuno-restorative response within the study observation period (including the 2-month
period following cessation of the 28 days of treatment), measured by one or more of the
following immunological parameters:
- Increase in natural killer (NK) cell activity.
- Increase in total T-cells (OKT-11).
- Increases in absolute number and percentage of T-helper cells (OKT-4).